Sunvozertinib and Digoxin: Interaction Details
AI-assisted, pharmacist-reviewed · Source data updated Aug 8, 2026 · Sources: FDA labeling, DDInter 2.0, cited literature
Digoxin
Sunvozertinib
How we grade severity & evidence
Severity levels
- Contraindicated: These should generally not be used together.
- Major: Potentially serious — often needs a change or close monitoring.
- Moderate: Can be significant — usually manageable with monitoring.
- Minor: Usually limited clinical impact.
Evidence grades
- Established: Well documented — supported by controlled studies or strong clinical data.
- Probable: Good supporting evidence, though not definitively proven.
- Suspected: Some evidence suggests this interaction, but it is not well established.
- Possible: Limited or conflicting evidence; the interaction may occur.
- Theoretical: Predicted from the drugs' pharmacology; not yet confirmed in people.
Ratings come from the documented interaction literature and are reviewed by a pharmacist. They describe the documented risk of the combination, not what will necessarily happen to you — your dose, timing, and health picture all matter.
What happens
Increased P-gp substrates with NTI exposure and increased risk of P-gp substrates with NTI-related adverse effects
Interaction Deep Dive
Coadministration of sunvozertinib with P-gp substrates having narrow therapeutic index (NTI) increases exposure of P-gp substrates, which may increase the risk of adverse reactions related to these substrates. In a drug interaction study, digoxin (P-gp substrate) AUC increased by 1.4-fold and Cmax by 1.2-fold following concomitant administration of sunvozertinib. Monitor for increased adverse reactions of P-gp substrates where minimal concentration changes may lead to serious adverse reactions, when coadministered with sunvozertinib1.
Why it happens (mechanism)
Inhibition of P-gp-mediated efflux transport by sunvozertinib
Literature reports
1 report — tap to read
a) In a drug interaction study, digoxin (P-gp substrate) AUC increased by 1.4-fold and Cmax by 1.2-fold following concomitant administration of sunvozertinib 1.
Common questions
Can I take Sunvozertinib and Digoxin together?
Increased P-gp substrates with NTI exposure and increased risk of P-gp substrates with NTI-related adverse effects Always confirm with your pharmacist or prescriber before making any change.
How serious is the Sunvozertinib and Digoxin interaction?
It is rated major. Potentially serious — often needs a change or close monitoring.
How quickly could this interaction happen?
The documented onset is "unspecified". The timing of this interaction is not well characterized.
How strong is the evidence for this interaction?
The evidence is graded "theoretical". Predicted from the drugs' pharmacology; not yet confirmed in people.
Questions for your pharmacist
- Does my dose of Sunvozertinib or Digoxin need adjusting while I take them together?
- What symptoms should prompt me to call you or my prescriber right away?
- Does the timing of my doses matter for this combination?
- Is there a safer alternative to one of these medications for me?
References (1)
- Product Information: ZEGFROVY(TM) oral tablets, sunvozertinib oral tablets. Dizal (Jiangsu) Pharmaceutical Co. Ltd (per FDA), Shanghai, China, 2025.
Keep reading about Digoxin
Keep reading about Sunvozertinib
These medications also interact with supplements
Prescription drugs aren't the whole picture — herbal and dietary supplements can interact with them too. From the evidence-graded Natural Medicines database:
major · moderate · minor — check everything you take with our drug–supplement interaction checker.
Check another combination
Our instant two-drug interaction checker is almost here.
Still have questions about this combination?
Every question gets a real answer from a licensed pharmacist — free, and usually within a day.
Ask the pharmacist